Umbilical cord-derived mesenchymal stromal cell infusion improves blood sugar control in patients with type II diabetes

      Diabetes is a systemic disease with end-organ complications secondary to hyperglycaemia and tissue ischaemia. In Type II Diabetes Mellitus (T2DM), there is initially insulin resistance followed by insulin depletion due to beta-islet cell dysfunction. We have previously demonstrated that mesenchymal stromal cell (MSC) may be induced to become insulin-producing cells in-vitro. MSC may also alleviate beta-islet cell dysfunction and improve skeletal muscle responsiveness to insulin. Therefore we postulate that MSC could further improve glycaemic control when added to conventional medical therapy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect